

14 November 2024

*This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.*

**BEXIMCO PHARMACEUTICALS LIMITED.**

**Financial Results for the First Quarter Ended 30 September 2024**

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its unaudited results for the three-month period ended 30 September 2024. The financial statements have been released to the Dhaka and Chittagong Stock Exchanges in compliance with the requirements from the Bangladesh SEC.

**Beximco Pharma Managing Director, Iqbal Ahmed, commented:**

*"We have started the year with modest revenue growth in the face of ongoing macroeconomic challenges. However, as demonstrated in our recent strong full year results, through the resilience and underlying strengths of the business, we remain confident in executing on our growth strategy by providing high-quality and affordable medicines to patients, and ultimately delivering value for shareholders."*

This announcement is available in its entirety at [http://www.ms-pdf.londonstockexchange.com/ms/1409M\\_1-2024-11-13.pdf](http://www.ms-pdf.londonstockexchange.com/ms/1409M_1-2024-11-13.pdf)

**For further information please visit [www.beximcopharma.com](http://www.beximcopharma.com) or enquire to:**

**Beximco Pharma**

S M Rabbur Reza, Chief Operating Officer  
Tel: +880 2 58611001, Ext.20111

Mohammad Ali Nawaz, Chief Financial Officer  
Tel: +880 2 58611001, Ext.20030

**SPARK Advisory Partners Limited** (Nominated Adviser)

Mark Brady / Andrew Emmott  
Tel: +44 (0) 20 3368 3551 / 3555

**SP Angel Corporate Finance LLP** (Broker)

Matthew Johnson  
Tel: +44 (0) 20 3470 0470

**FTI Consulting**

Simon Conway / Victoria Foster Mitchell / Sam Purewal  
Tel: +44 (0) 20 3727 1000

**Notes to Editors**

**About Beximco Pharmaceuticals Limited**

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5700 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

QRFEXLFFZFLZFBX